Search Results

15 items found for " Ralf Westenfeld"

Posts (10)

Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its half-year
Nanobodies: New Dimensions in GPCR Signaling Research
Tailorable half-life: Nanobodies can extend their half-life through PEGylation or fusion to serum albumin This allows for tailoring the half-life of nanobodies to increase their therapeutic window depending
📰 GPCR Weekly News, August 7 to 13, 2023
disease therapy Primary cilia in skeletal development and disease Industry News Addex Reports 2023 Half Trial with Cancer Immunotherapy Drug HTL0039732 Exscientia Business Update for Second Quarter and First Half

Receptor autoantibodies: Associations with cardiac markers, histology, and function in human non-ischaemic heart failure
Authors Elric Zweck , Maximilian Karschnia , Daniel Scheiber , Harald Heidecke , Ralf Dechend , Carmen Barthuber , Sina Kaufmann , Malte Kelm , Michael Roden , Ralf Westenfeld , Julia Szendrödi , Fritz Boege
Ep 45 with Dr Ralf Jockers
Ralf Jockers About Dr. Ralf Jockers Ralf Jockers studied in Cologne and received a Ph.D. in biotechnology and biochemistry from Ralf Jockers on the web Jockers Lab WGDR-3545 Pubmed Dr.
Session V | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Authors & Affiliations "Fabian Pohl1, Florian Seufert2, Yin Kwan Chung3, Daniela Volke1, Ralf Hoffmann1